Heidy King-Jones - 01 Feb 2024 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Chief Legal Officer and Corporate Secretary
Signature
/s/ Heidy King-Jones
Issuer symbol
SYRE
Transactions as of
01 Feb 2024
Net transactions value
$0
Form type
4
Filing time
02 Feb 2024, 20:23:54 UTC
Previous filing
05 Sep 2023
Next filing
17 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Award $0 +63,000 $0.000000 63,000 01 Feb 2024 Common Stock 63,000 $25.86 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 63,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

Remarks:

Chief Legal Officer and Corporate Secretary